We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+16.12%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.94B
AUM Growth
+$295M
Cap. Flow
+$29.2M
Cap. Flow %
0.74%
Top 10 Hldgs %
26.69%
Holding
163
New
20
Increased
50
Reduced
30
Closed
15

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$44.7M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$22.4M
3
INZY
Inozyme Pharma
INZY
+$21.9M
4
KYMR icon
Kymera Therapeutics
KYMR
+$21.7M
5
HUM icon
Humana
HUM
+$20.7M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$41.5M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$32M
3
CI icon
Cigna
CI
+$30.2M
4
AMGN icon
Amgen
AMGN
+$29.7M
5
ALLO icon
Allogene Therapeutics
ALLO
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 90.05%
2 Consumer Staples 1.43%
3 Consumer Discretionary 0.93%
4 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRTC icon
1
iRhythm Holdings
IRTC
$3.85B
$149M 3.78%
625,000
-26,000
-4% -$4.6M
NBIX icon
2
Neurocrine Biosciences
NBIX
$16.8B
$141M 3.58%
1,465,500
+99,000
+7% +$11.5M
IMMU
3
DELISTED
Immunomedics Inc
IMMU
$135M 3.43%
1,587,500
-90,179
-5% -$4.56M
UNH icon
4
UnitedHealth
UNH
$376B
$126M 3.2%
405,000
– –
HUM icon
5
Humana
HUM
$43.7B
$100M 2.55%
242,500
+51,500
+27% +$20.7M
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$88.3M 2.24%
952,773
-7,256
-0.8% -$559K
ISRG icon
7
Intuitive Surgical
ISRG
$127B
$85.1M 2.16%
360,000
– –
CNC icon
8
Centene
CNC
$30.7B
$77M 1.95%
1,320,000
+5,000
+0.4% +$311K
ARGX icon
9
argenx
ARGX
$53.4B
$75.5M 1.92%
287,500
– –
PODD icon
10
Insulet
PODD
$11.5B
$74.6M 1.89%
315,500
+22,500
+8% +$4.74M
ZLAB icon
11
Zai Lab
ZLAB
$2.06B
$68.5M 1.74%
823,527
+10,281
+1% +$825K
NVTA
12
DELISTED
Invitae Corporation
NVTA
$65.8M 1.67%
1,517,962
+6,835
+0.5% +$233K
ACAD icon
13
Acadia Pharmaceuticals
ACAD
$4.43B
$64.9M 1.65%
1,573,200
+518,200
+49% +$22.4M
NVAX icon
14
Novavax
NVAX
$1.2B
$63.5M 1.61%
585,705
+15,107
+3% +$1.84M
HCA icon
15
HCA Healthcare
HCA
$87.2B
$62.3M 1.58%
500,000
-49,500
-9% -$6.13M
ONC
16
BeOne Medicines Ltd
ONC
$32.8B
$61.6M 1.56%
215,000
– –
PCRX icon
17
Pacira BioSciences
PCRX
$1.04B
$60.4M 1.53%
1,005,000
+80,000
+9% +$4.65M
MRTX
18
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$57.9M 1.47%
348,761
– –
FRPT icon
19
Freshpet
FRPT
$2.93B
$56.6M 1.43%
506,500
+30,500
+6% +$3.1M
AGIO icon
20
Agios Pharmaceuticals
AGIO
$1.79B
$55.4M 1.4%
1,581,509
+401,789
+34% +$17.6M
NVRO
21
DELISTED
NEVRO CORP.
NVRO
$53.8M 1.36%
386,000
– –
BAX icon
22
Baxter International
BAX
$13.5B
$51.9M 1.32%
645,000
– –
HZNP
23
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$50.5M 1.28%
+650,000
New +$44.7M
ALNY icon
24
Alnylam Pharmaceuticals
ALNY
$27.5B
$49.5M 1.26%
339,814
-5,186
-2% -$737K
IDXX icon
25
Idexx Laboratories
IDXX
$44.1B
$49.1M 1.25%
125,000
– –
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Rock Springs Capital Management held 163 positions worth $3.94B, up 8.1% from $3.65B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q3 2020 filing shows 20 new, 50 increased, 30 reduced and 15 closed positions. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 650,000 shares worth $50.5M. The largest sale was Portola Pharmaceuticals, Inc., an estimated $41.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q3 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 650,000 shares worth $50.5M.
  • Rock Springs Capital Management added most to Acadia Pharmaceuticals in Q3 2020, an estimated $22.4M increase.
  • Rock Springs Capital Management's biggest Q3 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $32M.
  • Rock Springs Capital Management fully exited Portola Pharmaceuticals, Inc. in Q3 2020, selling an estimated $41.5M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $3.94B portfolio in Q3 2020.
  • Rock Springs Capital Management opened 20 new positions and closed 15 in Q3 2020.
  • Rock Springs Capital Management's portfolio value rose 8.1% quarter-over-quarter to $3.94B.

Based on Rock Springs Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.